Conference Track

Updates in HBV Management

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Pradefovir Demonstrates Better Pharmacokinetic and Pharmacodynamic (Antiviral Activity) Properties Than Adefovir, According to Preliminary Results
Greater Virologic Efficacy of Entecavir vs Lamivudine After 2 Years of Treatment in HBeAg-Negative Chronic Hepatitis B Patients
Responses to Peginterferon Alfa-2a Monotherapy Durable at 1 Year Posttreatment in Patients With HBeAg-Positive Chronic HBV Infection
Week 24 Virologic Responses to Telbivudine or Lamivudine Predict Later Outcomes in Patients with Chronic HBV
48-Week Regimen of Clevudine Appears Safe and Effective in Nucleoside-Naive Patients With Chronic HBV Infection
Prolonged Treatment With Entecavir Induces Continued Response in Lamivudine-Refractory, HBeAg-Positive, Chronic Hepatitis B Patients
Telbivudine Superior to Lamivudine Across Most HBeAg-Positive and HBeAg-Negative Patient Subgroups
Adefovir Plus Lamivudine Superior to Adefovir Monotherapy in Italian Patients With Lamivudine-Resistant Chronic HBV Infection
Close Monitoring of HBV Transplant Patients on Lamivudine ± HBIg Prophylaxis Warranted to Quickly Detect HBV Recurrence
No HBV Transmission to Anti-HBc–Negative Patients Receiving Nonliver Organ Transplants From Anti-HBc–Positive Donors
Taiwan Infant HBV Vaccination Program Effective for Reducing the Incidence of HCC
Relationship Between HBV-Specific T-Cell Responses, HBV DNA, and ALT Dynamic in Anti-HBe–Positive Patients With Chronic HBV Infection
Adefovir Resistance Mutations Rare and Slow to Develop During 5 Years of Treatment in HBeAg-Negative Patients
Suboptimal Responses to Entecavir Not Associated With Entecavir-Emergent Resistance Mutations in Nucleoside-Naive Patients With No Lamivudine Resistance Mutations
Efficacy and Resistance Outcomes With Long-term Adefovir Monotherapy in Patients With Lamivudine-Resistant, Chronic Genotype C HBV Infection
Entecavir Superior to Lamivudine for Improving Advanced Fibrosis in Patients With Chronic Hepatitis B
Pradefovir Safe and Effective in Treatment of Chronic Hepatitis B Virus
Peginterferon alfa-2a Associated With Prolonged Biochemical and Antiviral Response in HBeAg-Negative Chronic Hepatitis B Patients

Expert Analysis

Updates in HBV Management

Faculty:
Yves Benhamou, MD, PhD Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the results of recent studies evaluating the use of US Food and Drug Administration–approved agents in the treatment of hepatitis B virus (HBV) infection, including results related to drug resistance, predictors of response, and utility in special populations such as patients awaiting transplant
Discuss the results of trials of drugs in development for the treatment of HBV infection
Describe new data regarding predictors of hepatocellular carcinoma and risks of acquiring HBV through donor cells, tissues, and organs

CME CREDIT INFORMATION

Release Date: 06/28/06

Expiration Date: 06/27/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.